Vyvanse

Vyvanse is Adderall with a seatbelt. The molecule you swallow, lisdexamfetamine, has an amino acid (lysine, one of the building-block amino acids your body uses for everything) stapled onto a regular d-amphetamine molecule. In that form it does basically nothing. It has to ride to your red blood cells, where an enzyme slowly clips the lysine off, and only then do you have free amphetamine floating around in your bloodstream. That’s the whole trick. Everything interesting about how Vyvanse feels and how it doses out comes from that one piece of chemistry. Full disclosure up front, this is the stimulant I’m on myself, it’s the one I reach for first in most adults, and I’m not pretending to be neutral about it.

Vyvanse is Adderall with a seatbelt.

The practical consequence is that the curve is smooth. There’s no IR-style peak at ninety minutes and no obvious cliff four hours later… the enzymatic conversion paces the release on its own, and it paces it pretty consistently from person to person. You get a long, gentle ramp, a long plateau, and a slow taper. Ten to fourteen hours of working medication for most people, depending on dose and how fast you metabolize.

It’s a Schedule II amphetamine prodrug, FDA-approved for ADHD in 2007 and for binge eating disorder (BED, the official name for the eating pattern where people binge until they’re physically uncomfortable, then shame-spiral, then promise themselves tomorrow’s a fresh start, repeat) in 2015. The BED indication is the one most patients have never heard of, and it’s the one that changes who Vyvanse is for. We’ll get to that in a minute.

Why the prodrug delay actually matters

People sometimes hear “prodrug” and assume it’s marketing. It isn’t. The lysine doesn’t come off until the molecule hits the bloodstream and meets the right peptidase. You can’t snort it, you can’t shoot it, you can’t crush it and chew it for a faster hit, the enzymatic step is the rate-limiter, and the enzyme doesn’t care what route you took. The abuse liability isn’t zero, but the euphoric peak that drives most amphetamine misuse is significantly blunted because there’s no sharp spike to chase. Which, if we’re being honest, is exactly the kind of design decision the field needed more of and got less of.

That same blunting is what most ADHD patients actually want. With Vyvanse, most people don’t feel a kick-in moment. They notice an hour or two in that they’ve been working on the same task without getting up, and that’s the medication. Not feeling it come on is the whole appeal for a lot of guys, they came in to get their day handled and a buzz at the desk was never the goal. The bro-internet treats that as the drug failing, but that’s mostly people chasing a high they were never supposed to get in the first place.

The “I miss my Adderall IR” patient

This pattern comes up a lot. A guy has been on Adderall IR (immediate-release, the short-acting tablets) twice a day for years, productive enough, but the cycle is getting to him. First dose at 7 AM, kick in around 8:30, ride until noon, crash through lunch, second dose at 12:30, ride to five, crash through the evening. He wants off the rollercoaster. We convert him to Vyvanse at a roughly equivalent dose.

Three weeks in he comes back unhappy. The medication “wasn’t working.” When we get into it, what he means is that he can’t feel it. He’d been using the IR kick as his internal cue that he was now in work mode, and without anything to feel kick in, he’s sitting at his desk at 9 AM waiting for something to happen, and when nothing does, he assumes the medication has failed. Pull his task data and he’s actually shipped more code in those three weeks than the month before. The medication is working fine… what failed was his ritual.

That’s the most common version of the Vyvanse-disappointment story. If your IR doses were also functioning as a structuring cue for “now we work,” the smooth release is going to feel like nothing for the first month while your brain rebuilds the cue. Most people get past it. Some don’t, and end up back on IR. Both are reasonable. The drug isn’t the wrong drug, the workflow just needed a different anchor.

Not feeling it come on is the whole appeal for a lot of guys, a buzz at the desk was never what they came in for.

Conversion math and dosing strategy

The rough conversion most psychiatrists use runs about two and a half to one, so 30mg of Vyvanse is in the ballpark of 12 to 15mg of total daily Adderall, 50mg lands around 20mg, and the 70mg cap is roughly a 30mg Adderall dose. It’s rough, individual variability is real, and the comparison isn’t apples to apples because the IR doses pulse and Vyvanse doesn’t. It also means Vyvanse has a lower ceiling than people expect, since 70mg is about as high as it goes and that’s only around 30mg of Adderall, so if a guy genuinely needs more amphetamine than that, Vyvanse can’t get him there, which is one of the honest reasons somebody stays on Adderall.

The usual start in adults is 30mg, hold for a week, titrate up by 10 or 20mg at a time. Most adults land between 50 and 70mg. Seventy is the FDA ceiling, and there are very few patients who genuinely need more. When the ceiling does start to feel low, the move I’d rather make is to augment with a small IR booster in the late afternoon instead of chasing a higher prodrug load… it’s cleaner pharmacology and easier on the cardiovascular system.

The cardiac caveat applies here the same way it applies to every stimulant. Anyone over 50 starting a stimulant for the first time, anyone on cardiac meds already, anyone with a family history of arrhythmia, this is a fraught conversation and it should be. The risk isn’t zero, and any prescriber who tells you stimulants are completely safe in someone with a real cardiac substrate is a damn liar. Get baseline vitals, an EKG if there’s any reason at all, recheck pulse and BP at every visit. Not to be Chicken Little about it, but the kind of guy who shows up dismissive about the cardiac piece because his coworker has been on Adderall since college is exactly the guy I want to slow down with. Different bodies, different math, different ages.

About the afternoon crash question that comes up all the time. People ask me constantly whether Vyvanse crashes. It tapers more gently than IR amphetamines, which most patients describe as “no crash” or “barely any crash.” Maybe one in five still get a real afternoon dip around hour ten or eleven, usually irritability and brain fog rather than the full IR-style collapse. The fix is either a small IR booster (5mg of dextroamphetamine at 3 PM) or accepting the dip and structuring the evening around it. The honest answer is the second one, when you can swing it, because stacking a short-acting on top of a long-acting starts to add up to a lot of total amphetamine and you don’t get that back.

Binge eating disorder, which most patients have never heard of

This is the indication that gets missed, and missing it costs guys years of suffering. Vyvanse is the only FDA-approved medication for binge eating disorder in adults. Appetite does drop on it, but the cheap stimulant appetite-suppression story doesn’t explain what’s happening. The mechanism appears to be the same impulse-control and reward-modulation work the drug does for ADHD, applied to the eating loop. Patients with BED report fewer binge episodes, smaller binges when they happen, and longer gaps between them. The effect shows up at the 50 to 70mg range, similar to ADHD dosing.

What’s nice to hear, because most posts about BED lead with the misery and bury the relief: when this works, it works fast. Patients who’ve spent years in the binge-shame-promise-binge loop describe the loop just… easing, the cravings quieting, the late-night standing-at-the-counter thing stopping. It’s not weight-loss-pill territory. It’s the loop letting go. That’s a different thing, and it’s the thing the loop has been making feel impossible.

Say you’ve got a guy who comes in for what he thinks is depression. Weight has been climbing for a while, mood is awful, and when we talk about his eating it turns out to be textbook BED, late-night binges three or four nights a week, eating until physically uncomfortable, then shame, then promising himself he’d be “good” tomorrow, then doing the same thing forty-eight hours later. He’s been to a couple of therapists and a nutritionist. Nobody named it. Start Vyvanse at 30, titrate to 50, and within two months the binge frequency has dropped to maybe twice a month and is still falling. The depression, which had been driven mostly by the shame loop around the bingeing, lifts on its own. He didn’t have a primary depression. He had untreated BED for years, and his mood was riding on the loop.

If you’re reading this and any of that sounds familiar, ask your prescriber whether you have a binge pattern, and whether anybody has actually screened you for it. Most clinicians don’t ask. You usually have to bring it up yourself, which is annoying and unfair and is also how the system currently works.

Why some patients prefer it over Concerta

Concerta is a fine long-acting methylphenidate. The osmotic pump (the controlled-release mechanism inside the pill that pushes drug out at a steady rate) gives you a reasonable workday of coverage, eight to twelve hours. Vyvanse pulls ahead for some patients because the curve is smoother in the back half of the day (no mechanical pump to empty at a predictable rate), and because a subset of patients who didn’t respond to methylphenidate respond fine to amphetamine, and vice versa. Pharmacology being weird in ways you can’t predict from the chart.

That doesn’t make Vyvanse the right starting medication for everybody. For kids and adolescents I usually start with methylphenidate because the appetite suppression is less of a growth issue, which matters when somebody is actively trying to get taller. For adults with clean ADHD and no cardiovascular flags, Vyvanse usually goes to the front of the line. For adults with a binge pattern, Vyvanse moves to the front of the line regardless of whether they call the binge pattern a problem yet.

Where I land on the prescribing call

The thing I want to say out loud, because it sometimes gets lost in the receptor talk: if a guy walks in and wants Vyvanse and meets criteria, he gets Vyvanse. I’m a provider, not a parent. My job is to lay out the honest take on what’s likely to work, what the trade-offs are, what I’d watch for, and what the cardiac picture looks like. His job is the choice. The most I’ll do, in cases where I have reservations, is make it a disapproving yes… the script gets written, with a real conversation about what I want to keep an eye on and why I wasn’t thrilled about it. I hardly ever say no. The appointment isn’t mine, it’s his.

The prodrug design isn’t magic and it isn’t risk-free. It’s a Schedule II amphetamine and it deserves the respect every Schedule II gets. But the smoothness it buys, the BED indication nobody talks about, and the lower abuse-spike profile are the reasons it’s the long-acting stimulant most adults end up on first. That’s not a marketing claim. It’s the math after watching enough patients work through enough other stimulants to know what most of them want, which is the medication that does the work without making them feel like they took the medication.

Sources

1. Cortese S, Adamo N, Del Giovane C, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2018;5(9):727-738. PMID 30097390.
2. Faraone SV, Banaschewski T, Coghill D, et al. The World Federation of ADHD International Consensus Statement: 208 Evidence-based conclusions about the disorder. Neurosci Biobehav Rev. 2021;128:789-818. PMID 33549739.
3. Habel LA, Cooper WO, Sox CM, et al. ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. JAMA. 2011;306(24):2673-2683. PMID 22161946.
4. McElroy SL, Hudson JI, Mitchell JE, et al. Efficacy and safety of lisdexamfetamine for treatment of adults with moderate to severe binge-eating disorder: a randomized clinical trial. JAMA Psychiatry. 2015;72(3):235-246. PMID 25587645.